RAPT vs. FHTX, VSTM, HOWL, AKBA, IXHL, RIGL, XOMA, ACIU, STOK, and PBYI
Should you be buying RAPT Therapeutics stock or one of its competitors? The main competitors of RAPT Therapeutics include Foghorn Therapeutics (FHTX), Verastem (VSTM), Werewolf Therapeutics (HOWL), Akebia Therapeutics (AKBA), Incannex Healthcare (IXHL), Rigel Pharmaceuticals (RIGL), XOMA (XOMA), AC Immune (ACIU), Stoke Therapeutics (STOK), and Puma Biotechnology (PBYI). These companies are all part of the "pharmaceutical preparations" industry.
RAPT Therapeutics (NASDAQ:RAPT) and Foghorn Therapeutics (NASDAQ:FHTX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, media sentiment, community ranking, risk, earnings, institutional ownership, analyst recommendations, valuation and profitability.
RAPT Therapeutics received 60 more outperform votes than Foghorn Therapeutics when rated by MarketBeat users. Likewise, 68.75% of users gave RAPT Therapeutics an outperform vote while only 56.00% of users gave Foghorn Therapeutics an outperform vote.
99.1% of RAPT Therapeutics shares are held by institutional investors. Comparatively, 63.9% of Foghorn Therapeutics shares are held by institutional investors. 5.5% of RAPT Therapeutics shares are held by company insiders. Comparatively, 9.2% of Foghorn Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
RAPT Therapeutics has a net margin of 0.00% compared to Foghorn Therapeutics' net margin of -288.17%. Foghorn Therapeutics' return on equity of 0.00% beat RAPT Therapeutics' return on equity.
Foghorn Therapeutics has higher revenue and earnings than RAPT Therapeutics. RAPT Therapeutics is trading at a lower price-to-earnings ratio than Foghorn Therapeutics, indicating that it is currently the more affordable of the two stocks.
RAPT Therapeutics has a beta of 0.47, indicating that its stock price is 53% less volatile than the S&P 500. Comparatively, Foghorn Therapeutics has a beta of 3.17, indicating that its stock price is 217% more volatile than the S&P 500.
In the previous week, RAPT Therapeutics had 2 more articles in the media than Foghorn Therapeutics. MarketBeat recorded 4 mentions for RAPT Therapeutics and 2 mentions for Foghorn Therapeutics. Foghorn Therapeutics' average media sentiment score of 1.22 beat RAPT Therapeutics' score of 0.66 indicating that Foghorn Therapeutics is being referred to more favorably in the news media.
RAPT Therapeutics currently has a consensus target price of $25.89, suggesting a potential upside of 210.79%. Foghorn Therapeutics has a consensus target price of $14.83, suggesting a potential upside of 148.46%. Given RAPT Therapeutics' higher possible upside, equities analysts plainly believe RAPT Therapeutics is more favorable than Foghorn Therapeutics.
Summary
Foghorn Therapeutics beats RAPT Therapeutics on 10 of the 18 factors compared between the two stocks.
Get RAPT Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for RAPT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RAPT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
RAPT Therapeutics Competitors List
Related Companies and Tools